Short answer
CATALYST PHARMACEUTICALS, INC. (CPRX) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $148M (up 15.3% year over year) with net income of $53M.
Q3 2025 key financials · XBRL
- Revenue
- $148M
- +15.3% YoY · +1.2% QoQ
- Net income
- $53M
- +20.3% YoY · +1.3% QoQ
- Operating margin
- 44.7%
- EPS (diluted)
- $0.41
- +17.1% YoY · +0.0% QoQ
Source: XBRL data from the CATALYST PHARMACEUTICALS, INC. (CPRX) Q3 2025 10-Q on SEC EDGAR. USD.
CATALYST PHARMACEUTICALS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability or margin data included in MD&A section
- No cash position, operating cash flow, or capital deployment details mentioned
- Management highlights potential tariffs on pharmaceutical imports, risks to supply chain costs, and impact on clinical trials and product sales
- President Trump's MFN pricing proposals may affect drug pricing for Medicaid and Medicare with uncertain financial impact
Risk Factors
- New risk: generic competition for FYCOMPA® tablets began entering market, threatening revenue and potential intangible asset impairment
- Updated legal risk: ongoing litigation enforcement against Paragraph IV challenger seeking generic FIRDAPSE® entry intensified
- Regulatory risk: pricing pressures from Inflation Reduction Act of 2022 and potential Most Favored Nation pricing or 100% tariffs on imports
- Operational risk: reliance on third party suppliers and contract manufacturers maintaining cGMP and timely product supply
- Financial risk: uncertainty in payor coverage and reimbursement levels impacting product pricing and revenue realization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CATALYST PHARMACEUTICALS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.